PlainRecalls
FDA Drug Moderate Class II Terminated

Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06

Reported: September 14, 2016 Initiated: May 9, 2016 #D-1491-2016

Product Description

Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06

Reason for Recall

Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.

Details

Units Affected
14,808 bottles
Distribution
US Nationwide
Location
Pennington, NJ

Frequently Asked Questions

What product was recalled?
Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06. Recalled by Zydus Pharmaceuticals USA Inc. Units affected: 14,808 bottles.
Why was this product recalled?
Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 14, 2016. Severity: Moderate. Recall number: D-1491-2016.